Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
12
Active, not recruiting, industry sponsors, Rare and genetic disease, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
12 trials
Showing 1 to 12, recently updated first.
- Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Active, not recruiting
Prevail TherapeuticsIndustry
NCT04411654 · 7 participants · Start Jun 29, 2021 · Primary completion Feb 2027
Drug: Methylprednisolone; Sirolimus and 1 more · For: Gaucher Disease, Type 2
Sites: Oakland, California; Minneapolis, Minnesota; New York, New York · 6 sites in all
- Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)Active, not recruiting
Prevail TherapeuticsIndustry
NCT04127578 · 32 participants (planned) · Start Jan 3, 2020 · Primary completion Aug 31, 2031
Drug: LY3884961; Methylprednisolone and 1 more · For: Parkinson Disease
Sites: Scottsdale, Arizona; Murrieta, California; Englewood, Colorado · 15 sites in all
- An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIBActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT06488924 · 10 participants (planned) · Start Nov 5, 2024 · Primary completion Apr 30, 2030
Drug: JR-446 · For: Mucopolysaccharidosis III-B
Sites: Hiroshima, Japan; Okinawa, Japan; Tokyo, Japan · 4 sites in all
- Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)Active, not recruiting
GC Biopharma CorpIndustry
NCT06567769 · 9 participants (planned) · Start Nov 21, 2024 · Primary completion Jun 2027
Drug: GC1130A · For: Sanfilippo Syndrome Type A
Sites: Oakland, California; Minneapolis, Minnesota; Suwon, South Korea · 4 sites in all
- Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIAActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT06095388 · 15 participants · Start Oct 4, 2023 · Primary completion Oct 31, 2029
Drug: JR-441; JR-441 and 1 more · For: Mucopolysaccharidosis III-A
Sites: Hamburg, Germany
- A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male ParticipantsActive, not recruiting
Yuhan CorporationIndustry
NCT06517914 · 94 participants · Start Jul 29, 2024 · Primary completion Mar 2027
Drug: YH35995; Placebo · For: Healthy Participants
Sites: Seongnam, South Korea
- Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 GangliosidosisActive, not recruiting
Gemma BiotherapeuticsIndustry
NCT04713475 · 26 participants (planned) · Start Mar 17, 2021 · Primary completion Feb 2028
Drug: PBGM01 · For: GM1 Gangliosidosis; GM1 Gangliosidosis, Type I; GM1 Gangliosidosis, Type 2 and 1 more
Sites: Oakland, California; Minneapolis, Minnesota; New Brunswick, New Jersey · 7 sites in all
- A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With PhenylketonuriaActive, not recruiting
SanofiSanofi (SNY)
NCT05972629 · 32 participants (planned) · Start Aug 7, 2023 · Primary completion Apr 2, 2030
Drug: SAR444836 · For: Phenylketonuria
Sites: San Francisco, California; Aurora, Colorado; Gainesville, Florida · 11 sites in all
- A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter SyndromeActive, not recruiting
Denali Therapeutics Inc.Industry
NCT04251026 · 47 participants · Start Jul 16, 2020 · Primary completion Feb 2031
Drug: tividenofusp alfa · For: Mucopolysaccharidosis II
Sites: Oakland, California; Chicago, Illinois; Chapel Hill, North Carolina · 7 sites in all
- AAV Gene Therapy Study for Subjects with PKUActive, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT04480567 · 100 participants (planned) · Start Sep 24, 2020 · Primary completion Dec 2027
Drug: BMN 307 · For: Phenylketonuria (PKU)
Sites: Tampa, Florida; Morristown, New Jersey; Birmingham, United Kingdom
- A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ⅡActive, not recruiting
GC Biopharma CorpIndustry
NCT05422482 · 12 participants (planned) · Start Sep 20, 2022 · Primary completion Jun 2027
Drug: GC1123 · For: Mucopolysaccharidosis II; Hunter Syndrome
Sites: Pusan, South Korea; Seoul, South Korea · 3 sites in all
- An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry DiseaseActive, not recruiting
4D Molecular TherapeuticsIndustry
NCT04519749 · 18 participants (planned) · Start Sep 1, 2020 · Primary completion Jan 2026
Drug: 4D-310 · For: Fabry Disease
Sites: La Jolla, California; Atlanta, Georgia; Pittsburgh, Pennsylvania · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.